Erytech Pharma S.A.
ERYTECH to Host Fourth Quarter and Full Year 2018 Conference Call and Business Update
LYON, France, March 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2018 conference call and webcast on Tuesday, March 12, 2019, at 1:30 PM CET/8:30 AM EST to discuss operational highlights.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 3291426#
: +1 (833) 818-6807
International Dial-In Number : +1 (409) 350-3501
: +33 1 76 74 89 88
United-Kingdom : +44 2031070289
The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/bdbuhozf
An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056 , Conference ID: 3291426 # . An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com .
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.
ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in preparations to enter Phase 2 clinical development for the treatment of triple-negative breast cancer. ERYTECH’s next product candidate erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers, has demonstrated promising preclinical results and is in preparations to enter Phase 1 clinical development.
ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies (ERYZYME).
ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility is under construction in New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Jobindex A/S18.3.2019 22:08:24 CET | Pressemeddelelse
Jobindex Årsrapport for 2018
Abeona Therapeutics Inc.18.3.2019 21:46:12 CET | Pressemeddelelse
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Open Compute Project Foundation15.3.2019 15:56:37 CET | Pressemeddelelse
Switch Datacenters’ Amsterdam 1 Datacenter Achieves OCP-Ready™ Status
IDEAL INDUSTRIES, INC.15.3.2019 15:09:31 CET | Pressemeddelelse
IDEAL INDUSTRIES, INC. Acquires Cree Commercial Lighting and Intelligent Lighting Control Systems
Bombardier Inc.14.3.2019 13:45:49 CET | Pressemeddelelse
Bombardier Announces Expiration of Early Tender Date and Amendments for its Cash Tender Offers for up to US$975,000,000 Aggregate Purchase Price of its 6⅛% Senior Notes due 2021 and its 8.750% Senior Notes due 2021
Teledyne DALSA14.3.2019 13:01:36 CET | Pressemeddelelse
New 3D laser profiler series excels at in-line measurement and inspection tasks
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum